People With OUD May Still Face Barriers To Treatment, Despite MAT Act

Story Updated Stakeholders applaud Congress and the Biden administration’s actions to increase the number of providers who can prescribe medication treatment for opioid use disorder, but they say potential barriers to patients accessing treatments like buprenorphine are still posed by pharmaceutical companies, distributors and health care providers. Lobbyists also continue to push Congress and the administration to allow telehealth prescribing of buprenorphine, a flexibility that will expire at the end of the public health emergency. The White...